Figma Shares Indicated To Open $105/$110
Walgreens Boots Alliance, Inc. (NASDAQ:WBA), through its subsidiary Walgreens Boots Alliance Holdings LLC, recently reported significant stock transactions involving Cencora, Inc. (NYSE:COR), a prominent player in the Healthcare Providers & Services industry with a market capitalization of $47.7 billion. The company disclosed the sale of 1,087,885 shares of Cencora common stock, valued at approximately $264.5 million, at a price of $244.51 per share. Additionally, a private transaction sale of 204,491 shares, valued at $50 million, was made to Cencora. The transactions were part of a strategic financial maneuver involving early settlement agreements with financial institutions. Following these transactions, Walgreens Boots Alliance Holdings LLC retains ownership of 12,570,000 Cencora shares. Cencora, currently trading near its 52-week high with a 9.7% year-to-date return, has maintained dividend payments for 25 consecutive years and shows strong growth potential according to InvestingPro analysis, which indicates the stock is currently undervalued. Discover 13 additional key insights about Cencora with an InvestingPro subscription.
In other recent news, Cencora Inc. has seen significant activity from financial analysts and internal developments. Leerink Partners has raised their price target for Cencora to $301, maintaining an Outperform rating. This adjustment follows Cencora’s strong first-quarter results and is based on approximately 17 times the calendar year 2026 P/E. Meanwhile, Mizuho (NYSE:MFG) Securities initiated coverage on Cencora with an Outperform rating and a price target of $280, citing the company’s strong position in the Specialty/Biopharma Services sector. BofA Securities also revised its price target for Cencora, raising it to $260 due to increased confidence in Cencora’s technological innovation.
On the company’s internal front, Cencora announced the retirement of two long-standing board members, Richard W. Gochnauer and Kathleen W. Hyle. This change will reduce the board size from 13 to 11 members. Furthermore, Cencora has completed the acquisition of Retina Consultants of America, leading to an upward revision of its fiscal year 2025 adjusted earnings per share guidance.
These recent developments underscore the ongoing activity within Cencora, with analysts and the company itself indicating a positive outlook. It’s crucial for investors to keep an eye on these developments as they unfold.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.